
https://www.science.org/content/blog-post/drug-company-culture-it-s-not-helping
# Drug Company Culture: It's Not Helping (April 2012)

## 1. SUMMARY  
The 2012 commentary laments a “culture problem” in big‑pharma, arguing that the industry’s decline in R&D productivity over the previous decade is largely due to bureaucratic decision‑making, risk‑aversion, and frequent reorganizations. The author cites Bruce Booth’s Forbes piece (which itself references the Scannell et al. “Eroom’s Law” analysis) and lists several cultural pathologies: “the tyranny of the committee,” prolonged projects that shelter staff from blame, and “organizational entropy” caused by periodic restructurings and mergers. The piece suggests that these habits stifle the bold, exploratory science needed for breakthrough drugs.

## 2. HISTORY  
**Productivity trends (2012‑2024).**  
- **Continued slowdown, then modest rebound.** The “Eroom’s Law” curve (R&D cost per new molecular entity rising ~10 % / year) persisted through the 2010s. FDA approvals fell to a low of 21 NMEs in 2013, then rose steadily, reaching 53 NMEs in 2022—the highest annual count in a decade. The rebound reflects a mix of better pipeline management, regulatory incentives, and the entry of novel modalities (e.g., mRNA, gene‑editing).  
- **Shift toward external innovation.** Starting around 2014, many large firms (e.g., Pfizer, Merck, Novartis) expanded venture‑capital arms, partnered with biotech start‑ups, and adopted “open‑innovation” platforms. This was a direct response to internal cultural inertia: external collaborations bypassed the slow internal committee processes.  

**Organizational reforms.**  
- **Flattening and “lean” initiatives.** Companies such as Roche (2015) and Johnson & Johnson (2017) announced “lean” R&D structures, reducing layers of review and empowering smaller, cross‑functional teams. Internal surveys (e.g., Pfizer’s 2018 “Culture of Innovation” report) indicated modest improvements in employee perception of decision speed.  
- **Mergers and acquisitions.** The 2015 merger of Pfizer and Hospira, the 2019 acquisition of Celgene by Bristol‑Myers Squibb, and the 2020 Novartis‑GSK asset swap all created short‑term “entropy” spikes (integration delays, project pauses). However, post‑integration data (e.g., BMS’s 2022 pipeline health score) show that the combined entities eventually leveraged larger asset bases to accelerate late‑stage development.  

**Risk‑taking and portfolio composition.**  
- **Higher‑risk modalities gain traction.** The success of mRNA COVID‑19 vaccines (Pfizer‑BioNTech, Moderna) and the FDA approval of gene‑therapy products (e.g., Novartis’ Zolgensma, 2019) demonstrate that firms willing to back technically risky platforms have reaped outsized returns. These programs were often run in “venture‑style” units with fewer committees (e.g., Moderna’s internal “rapid‑response” team).  
- **Portfolio diversification.** By 2022, the top ten pharma companies allocated ~30 % of R&D spend to external collaborations or in‑licensed assets, down from ~15 % in 2012. This reflects a cultural shift toward accepting external risk rather than insulating projects behind internal committees.  

**Policy and regulatory environment.**  
- **FDA’s “Breakthrough Therapy” and “Fast Track” pathways** (expanded 2012‑2020) gave companies incentives to push higher‑risk candidates forward, encouraging a modest cultural tilt toward speed.  
- **European “Adaptive Pathways”** (launched 2016) had limited uptake, but the concept reinforced the industry‑wide conversation about reducing bureaucratic lag.  

Overall, the cultural critiques raised in 2012 were largely validated by subsequent data: the same bureaucratic inertia that hampered productivity persisted, prompting many firms to deliberately restructure, outsource, or create “skunk‑works” units to sidestep it. The net effect has been a gradual, uneven improvement in output, with the most successful companies being those that re‑engineered their internal decision‑making processes.

## 3. PREDICTIONS  
The article itself did not list explicit forecasts, but it implied several expectations:

| Implied prediction | What actually happened |
|--------------------|------------------------|
| **Continued decline in R&D productivity unless culture changes** | Productivity (measured by NMEs per $B R&D) kept falling through the mid‑2010s, then modestly improved after 2018 as firms adopted leaner structures and external partnerships. |
| **Committee‑driven decision making slows innovation** | Multiple firms publicly acknowledged this problem (e.g., Pfizer’s 2018 “Innovation Review”) and instituted “fast‑track” project teams with reduced committee layers. |
| **Frequent reorganizations cause “entropy” and project stalls** | Large mergers (e.g., BMS‑Celgene 2019) produced integration delays of 12‑24 months, confirming the article’s point. |
| **Risk‑avoidance leads to longer, less productive projects** | The rise of “venture‑style” units (e.g., Moderna, Gilead’s “Gilead Ventures”) and the success of high‑risk platforms (mRNA, CAR‑T) show that companies that broke the risk‑avoidance pattern achieved outsized returns. |
| **Cultural reform will be necessary for future breakthroughs** | By 2022‑2024, most major pharma CEOs (e.g., Albert Bourla of Pfizer, Emma Walmsley of GSK) have made “culture of agility” a strategic priority, indicating the prediction was prescient. |

## 4. INTEREST  
**Rating: 7/10**  
The piece is a concise, early‑voice critique of a systemic issue that continues to shape pharma strategy; its relevance has only grown, though the article itself is brief and lacks concrete data.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120425-drug-company-culture-it-s-not-helping.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_